C. Kent Osborne, M.D.

Professor

(832) 957-6500

Request Clinical Appointment

Email

kosborne@bcm.edu

Positions

Professor: Department of Medicine
Hematology Oncology
Baylor College of Medicine
Houston, Texas, United States
Breast Medical Oncologist Baylor St. Luke's Medical Center

Dudley and Tina Sharp Chair for Cancer Research: Baylor College of Medicine
Houston, Texas, United States

Founding Director: Dan L Duncan Comprehensive Cancer Center
Baylor College of Medicine
Houston, Texas, United States

Addresses

Dan L Duncan Comprehensive Cancer Center (Clinic): O’Quinn Medical Tower at Baylor St. Luke’s Medical Center’s McNair Campus
1919 Old Spanish Trail
Houston, TX, 77054
United States
Phone: (832) 957-6500
Fax: (713) 610-4595

Education

Advanced Training from National Cancer Institute: 06/1977 - Bethesda, Maryland, United States; Medical Oncology

Residency from Johns Hopkins Hospital: 06/1974 - Baltimore, Maryland, United States; Internal Medicine

M.D. from University of Missouri Medical School: 06/1972 - Columbia, Missouri, United States; Medicine

A.B. from University Of Missouri: 06/1968 - Columbia, Missouri, United States; Zoology

Fellowship at National Cancer Institute: Bethesda, MD; Medical Oncology

Residency at Johns Hopkins University Hospital: Baltimore, MD; Internal Medicine

MD from University of Missouri - Columbia School of Medicine: Columbia, MO

Certifications

American Board of Internal Medicine

American Board of Internal Medicine, Medical Oncology

Medical Oncology: #50803; American Board of Internal Medicine

Professional Interests

Diagnosis and treatment of breast cancer
Biology of breast cancer
Resistance to ER and HER2-targeted therapies in breast cancer
Breast Disease and Cancer

Websites

Dan L Duncan Comprehensive Cancer Center

Selected Publications

Hartmaier RJ, Richter AS, Gillihan RM, Sallit JZ, McGuire SE, Wang J, Lee AV, Osborne CK, O'Malley BW, Brown PH, Xu J, Skaar TC, Philips S, Rae JM, Azzouz F, Li L, Hayden J, Henry NL, Nguyen AT, Stearns V, Hayes DF, Flockhart DA, Oesterreich S. " A SNP in Steroid Receptor Coactivator-1 Disrupts a GSK3ß Phosphorylation Site and Is Associated with Altered Tamoxifen Response in Bone. " Mol. Endocrinol.. 2012 Feb ; 26 (2) : 220-7.
Pubmed PMID: 22174377.
Kessler JD, Kahle KT, Sun T, Meerbrey KL, Schlabach MR, Schmitt EM, Skinner SO, Xu Q, Li MZ, Hartman ZC, Rao M, Yu P, Dominguez-Vidana R, Liang AC, Solimini NL, Bernardi RJ, Yu B, Hsu T, Golding I, Luo J, Osborne CK, Creighton CJ, Hilsenbeck SG, Schiff R,. " A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. " Science. 2012 Jan 20; 335 (6066) : 348-53.
Pubmed PMID: 22157079.
Sun T, Aceto N, Meerbrey KL, Kessler JD, Zhou C, Migliaccio I, Nguyen DX, Pavlova NN, Botero M, Huang J, Bernardi RJ, Schmitt E, Hu G, Li MZ, Dephoure N, Gygi SP, Rao M, Creighton CJ, Hilsenbeck SG, Shaw CA, Muzny D, Gibbs RA, Wheeler DA, Osborne CK, Schi. " Activation of Multiple Proto-oncogenic Tyrosine Kinases in Breast Cancer via Loss of the PTPN12 Phosphatase. " Cell. 2011 Mar 4; 144 (5) : 703-18.
Pubmed PMID: 21376233.
Albain KS, Barlow WE, Ravdin PM, Farrar WB, Burton GV, Ketchel SJ, Cobau CD, Levine EG, Ingle JN, Pritchard KI, Lichter AS, Schneider DJ, Abeloff MD, Henderson IC, Muss HB, Green SJ, Lew D, Livingston RB, Martino S, Osborne CK. " Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. " Lancet. 2009 Dec 19; 374 (9707) : 2055-63.
Pubmed PMID: 20004966.
Rivkin SE, Green SJ, Lew D, Costanzi JJ, Athens JW, Osborne CK, Vaughn CB, Martino S. " Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of " Cancer. 2003 Jan 1; 97 (1) : 21-9.
Pubmed PMID: 12491501.
Schiff R, Massarweh SA, Shou J, Bharwani L, Arpino G, Rimawi M, Osborne CK. " Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. " Cancer Chemother. Pharmacol.. 2005 Nov ; 56 : 41567.
Pubmed PMID: 16273359.
Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taub. " American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). " Arch. Pathol. Lab. Med.. 2010 Jul ; 134 (7) : e48-72.
Pubmed PMID: 20586616.
Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taub. " American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. " Arch. Pathol. Lab. Med.. 2010 Jun ; 134 (6) : 907-22.
Pubmed PMID: 20524868.
Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taub. " American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. " J. Clin. Oncol.. 2010 Jun 1; 28 (16) : 2784-95.
Pubmed PMID: 20404251.
Friedman LC, Romero C, Elledge R, Chang J, Kalidas M, Dulay MF, Lynch GR, Osborne CK. " Attribution of blame, self-forgiving attitude and psychological adjustment in women with breast cancer. " J Behav Med. 2007 Aug ; 30 (4) : 351-7.
Pubmed PMID: 17497216.
Osborne CK, Schiff R. " Aromatase inhibitors: future directions. " J. Steroid Biochem. Mol. Biol.. 2005 May ; 95 (41279) : 183-7.
Pubmed PMID: 16019204.
Giuliano M, Schifp R, Osborne CK, Trivedi MV. " Biological mechanisms and clinical implications of endocrine resistance in breast cancer. " Breast. 2011 Oct ; 20 : S42-9.
Pubmed PMID: 22015292.
Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. " Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. " J. Clin. Oncol.. 2005 Oct 20; 23 (30) : 7721-35.
Pubmed PMID: 16234531.
Schiff R, Massarweh S, Shou J, Osborne CK. " Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. " Clin. Cancer Res.. 2003 Jan ; 9 (1) : 447S-54S.
Pubmed PMID: 12538499.
LaCroix AZ, Powles T, Osborne CK, Wolter K, Thompson JR, Thompson DD, Allred DC, Armstrong R, Cummings SR, Eastell R, Ensrud KE, Goss P, Lee A, Neven P, Reid DM, Curto M, Vukicevic S. " Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. " J. Natl. Cancer Inst.. 2010 Nov 17; 102 (22) : 1706-15.
Pubmed PMID: 21051656.
Rimawi MF, Osborne CK. " Breast Cancer: Blocking both driver and escape pathways improves outcomes. " Nat Rev Clin Oncol. 2012 ; 9 (3) : 133-4.
Pubmed PMID: 22330685.
Martin MD, Hilsenbeck SG, Mohsin SK, Hopp TA, Clark GM, Osborne CK, Allred DC, O'Connell P. " Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies. " Breast Cancer Res. Treat.. 2006 Jan ; 95 (1) : 41467.
Pubmed PMID: 16244788.
Davidson NE, O'Neill AM, Vukov AM, Osborne CK, Martino S, White DR, Abeloff MD. " Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). " J. Clin. Oncol.. 2005 Sep 1; 23 (25) : 5973-82.
Pubmed PMID: 16087950.
Malorni L, Shetty PB, De Angelis C, Hilsenbeck S, Rimawi MF, Elledge R, Osborne CK, De Placido S, Arpino G. " Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. " Breast Cancer Res. Treat.. 2012 Dec ; 136 (3) : 795-804.
Pubmed PMID: 23124476.
Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R, Bajetta E, Watanabe T, Morris C, Webster A, Dimery I, Osborne CK. " Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. " J. Clin. Oncol.. 2004 May 1; 22 (9) : 1605-13.
Pubmed PMID: 15117982.
Lippman ME, Benz C, Chinnaiyan A, Flockhart D, Harris A, Hudis C, Osborne CK, Press MF, Rae J, Sledge GW, Van't Veer L, Wicha M. " Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium 'Breast Cancer--The Development and Validation of New Therapeutics'. " Breast Cancer Res. Treat.. 2005 Mar ; 90 (1) : 41277.
Pubmed PMID: 15770520.
Tallman MS, Gray R, Robert NJ, LeMaistre CF, Osborne CK, Vaughan WP, Gradishar WJ, Pisansky TM, Fetting J, Paietta E, Lazarus HM. " Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. " N. Engl. J. Med.. 2003 Jul 3; 349 (1) : 17-26.
Pubmed PMID: 12840088.
Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK. " Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. " Clin. Cancer Res.. 2004 Jan 1; 10 (1) : 331S-6S.
Pubmed PMID: 14734488.
Osborne CK, Shou J, Massarweh S, Schiff R. " Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. " Clin. Cancer Res.. 2005 Jan 15; 11 (2) : 865s-70s.
Pubmed PMID: 15701879.
Arpino G, Wiechmann L, Osborne CK, Schiff R. " Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. " Endocr. Rev.. 2008 Apr ; 29 (2) : 217-33.
Pubmed PMID: 18216219.
Creighton CJ, Massarweh S, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Shou J, Malorni L, Schiff R. " Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. " Cancer Res.. 2008 Sep 15; 68 (18) : 7493-501.
Pubmed PMID: 18794137.
Wang YC, Morrison G, Gillihan R, Guo J, Ward RM, Fu X, Botero MF, Healy NA, Hilsenbeck SG, Phillips GL, Chamness GC, Rimawi MF, Osborne CK, Schiff R. " Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers -- role of estrogen receptor and HER2 reactivation. " Breast Cancer Res.. 2011 Dec ; 13 (6) : R121.
Pubmed PMID: 22123186.
Wang LH, Yang XY, Zhang X, An P, Kim HJ, Huang J, Clarke R, Osborne CK, Inman JK, Appella E, Farrar WL. " Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer. " Cancer Cell. 2006 Dec ; 10 (6) : 487-99.
Pubmed PMID: 17157789.
Rodriguez AA, Makris A, Wu MF, Rimawi M, Froehlich A, Dave B, Hilsenbeck SG, Chamness GC, Lewis MT, Dobrolecki LE, Jain D, Sahoo S, Osborne CK, Chang JC. " DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. " Breast Cancer Res. Treat.. 2010 Aug ; 123 (1) : 189-96.
Pubmed PMID: 20582464.
Morrison AJ, Herrera RE, Heinsohn EC, Schiff R, Osborne CK. " Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptor. " Mol. Endocrinol.. 2003 Aug ; 17 (8) : 1543-54.
Pubmed PMID: 12730327.
Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A. " Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. " J. Clin. Oncol.. 2002 Aug 15; 20 (16) : 3386-95.
Pubmed PMID: 12177098.
Lu C, Speers C, Zhang Y, Xu X, Hill J, Steinbis E, Celestino J, Shen Q, Kim H, Hilsenbeck S, Mohsin SK, Wakeling A, Osborne CK, Brown PH. " Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. " J. Natl. Cancer Inst.. 2003 Dec 17; 95 (24) : 1825-33.
Pubmed PMID: 14679152.
Strecker TE, Shen Q, Zhang Y, Hill JL, Li Y, Wang C, Kim HT, Gilmer TM, Sexton KR, Hilsenbeck SG, Osborne CK, Brown PH. " Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice. " J. Natl. Cancer Inst.. 2009 Jan 21; 101 (2) : 107-13.
Pubmed PMID: 19141783.
Osborne CK, Schiff R, Arpino G, Lee AS, Hilsenbeck VG. " Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. " Breast. 2005 Dec ; 14 (6) : 458-65.
Pubmed PMID: 16236516.
Schiff R, Osborne CK. " Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer. " Breast Cancer Res.. 2005 ; 7 (5) : 205-11.
Pubmed PMID: 16168139.
Lu H, Zhang Y, Roberts DD, Osborne CK, Templeton NS. " Enhanced gene expression in breast cancer cells in vitro and tumors in vivo. " Mol. Ther.. 2002 Dec ; 6 (6) : 783-92.
Pubmed PMID: 12498774.
Rimawi MF, Shetty PB, Weiss HL, Schiff R, Osborne CK, Chamness GC, Elledge RM. " Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. " Cancer. 2010 Mar 1; 116 (5) : 1234-42.
Pubmed PMID: 20082448.
Elledge RM, Green S, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P, Martino S, Osborne CK. " Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. " Int. J. Cancer. 2000 Mar 20; 89 (2) : 111-7.
Pubmed PMID: 10754487.
Fuqua SA, Schiff R, Parra I, Moore JT, Mohsin SK, Osborne CK, Clark GM, Allred DC. " Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. " Cancer Res.. 2003 May 15; 63 (10) : 2434-9.
Pubmed PMID: 12750263.
Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM. " Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. " J. Natl. Cancer Inst.. 2005 Sep 7; 97 (17) : 1254-61.
Pubmed PMID: 16145046.
Osborne CK, Schiff R, Fuqua SA, Shou J. " Estrogen receptor: current understanding of its activation and modulation. " Clin. Cancer Res.. 2001 Dec ; 7 (12) : 4338s-4342s; di.
Pubmed PMID: 11916222.
Robertson JF, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M, Kleeberg UR, Come SE, Vergote I, Gertler S, Buzdar A, Webster A, Morris C. " Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. " Cancer. 2003 Jul 15; 98 (2) : 229-38.
Pubmed PMID: 12872340.
Howell A, Pippen J, Elledge RM, Mauriac L, Vergote I, Jones SE, Come SE, Osborne CK, Robertson JF. " Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. " Cancer. 2005 Jul 15; 104 (2) : 236-9.
Pubmed PMID: 15937908.
Osborne CK, Wakeling A, Nicholson RI. " Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. " Br. J. Cancer. 2004 Mar ; 90 : S2-6.
Pubmed PMID: 15094757.
Osborne CK, Neven P, Dirix LY, Mackey JR, Robert J, Underhill C, Schiff R, Gutierrez C, Migliaccio I, Anagnostou VK, Rimm DL, Magill P, Sellers M. " Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor-Positive Metastatic Breast Cancer: A Randomized Phase II Study. " Clin. Cancer Res.. 2011 Mar 1; 17 (5) : 1147-59.
Pubmed PMID: 21220480.
Cleator S, Tsimelzon A, Ashworth A, Dowsett M, Dexter T, Powles T, Hilsenbeck S, Wong H, Osborne CK, O'Connell P, Chang JC. " Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance. " Breast Cancer Res. Treat.. 2006 Feb ; 95 (3) : 229-33.
Pubmed PMID: 16322899.
Chang JC, Makris A, Gutierrez MC, Hilsenbeck SG, Hackett JR, Jeong J, Liu ML, Baker J, Clark-Langone K, Baehner FL, Sexton K, Mohsin S, Gray T, Alvarez L, Chamness GC, Osborne CK, Shak S. " Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. " Breast Cancer Res. Treat.. 2008 Mar ; 108 (2) : 233-40.
Pubmed PMID: 17468949.
Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, O'Connell P. " Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. " Lancet. 2003 Aug 2; 362 (9381) : 362-9.
Pubmed PMID: 12907009.
Yao S, Barlow WE, Albain KS, Choi JY, Zhao H, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff M, Hortobagyi GN, Hayes DF, Ambrosone CB. " Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer. " Clin. Cancer Res.. 2010 Dec 15; 16 (24) : 6169-76.
Pubmed PMID: 21169260.
Osborne CK, Schiff R. " Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. " Breast. 2003 Dec ; 12 (6) : 362-7.
Pubmed PMID: 14659106.
Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK, Elledge RM. " HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. " Clin. Cancer Res.. 2004 Sep 1; 10 (17) : 5670-6.
Pubmed PMID: 15355892.
Townson SM, Sullivan T, Zhang Q, Clark GM, Osborne CK, Lee AV, Oesterreich S. " HET/SAF-B overexpression causes growth arrest and multinuclearity and is associated with aneuploidy in human breast cancer. " Clin. Cancer Res.. 2000 Sep ; 6 (9) : 3788-96.
Pubmed PMID: 10999774.
Oesterreich S, Allredl DC, Mohsin SK, Zhang Q, Wong H, Lee AV, Osborne CK, O'Connell P. " High rates of loss of heterozygosity on chromosome 19p13 in human breast cancer. " Br. J. Cancer. 2001 Feb ; 84 (4) : 493-8.
Pubmed PMID: 11207044.
Arpino G, Weiss HL, Clark GM, Hilsenbeck SG, Osborne CK. " Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. " J. Clin. Oncol.. 2005 Jul 20; 23 (21) : 4687-94.
Pubmed PMID: 15837971.
Liu Y, Ludes-Meyers J, Zhang Y, Munoz-Medellin D, Kim HT, Lu C, Ge G, Schiff R, Hilsenbeck SG, Osborne CK, Brown PH. " Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. " Oncogene. 2002 Oct 31; 21 (50) : 7680-9.
Pubmed PMID: 12400010.
Fuqua SA, Cui Y, Lee AV, Osborne CK, Horwitz KB. " Insights into the role of progesterone receptors in breast cancer. " J. Clin. Oncol.. 2005 Feb 1; 23 (4) : 931-2; author r.
Pubmed PMID: 15681552.
Creighton CJ, Casa A, Lazard Z, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Lee AV. " Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. " J. Clin. Oncol.. 2008 Sep 1; 26 (25) : 4078-85.
Pubmed PMID: 18757322.
Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, Chang JC. " Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. " J. Natl. Cancer Inst.. 2008 May 7; 100 (9) : 672-9.
Pubmed PMID: 18445819.
Hilsenbeck SG, Osborne CK. " Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial. " Clin. Cancer Res.. 2006 Feb 1; 12 (3) : 1049s-1055s.
Pubmed PMID: 16467123.
Martin MD, Fischbach K, Osborne CK, Mohsin SK, Allred DC, O'Connell P. " Loss of heterozygosity events impeding breast cancer metastasis contain the MTA1 gene. " Cancer Res.. 2001 May 1; 61 (9) : 3578-80.
Pubmed PMID: 11325822.
Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, Wong H, Narasanna A, Chakrabarty A, Hilsenbeck SG, Huang J, Rimawi M, Schiff R, Arteaga C, Osborne CK, Chang JC. " Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. " J. Clin. Oncol.. 2011 Jan 10; 29 (2) : 166-73.
Pubmed PMID: 21135276.
Hopp TA, Weiss HL, Parra IS, Cui Y, Osborne CK, Fuqua SA. " Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. " Clin. Cancer Res.. 2004 Nov 15; 10 (22) : 7490-9.
Pubmed PMID: 15569979.
Hammerich-Hille S, Bardout VJ, Hilsenbeck SG, Osborne CK, Oesterreich S. " Low SAFB levels are associated with worse outcome in breast cancer patients. " Breast Cancer Res. Treat.. 2010 Jun ; 121 (2) : 503-9.
Pubmed PMID: 19137425.
Yao S, Barlow WE, Albain KS, Choi JY, Zhao H, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff MD, Hortobagyi GN, Hayes DF, Ambrosone CB. " Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer. " Breast Cancer Res. Treat.. 2010 Nov ; 124 (2) : 433-9.
Pubmed PMID: 20309628.
Osborne CK, Schiff R. " Mechanisms of endocrine resistance in breast cancer. " Annu. Rev. Med.. 2011 Feb 18; 62 : 233-47.
Pubmed PMID: 20887199.
Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R. " Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. " J. Natl. Cancer Inst.. 2004 Jun 16; 96 (12) : 926-35.
Pubmed PMID: 15199112.
Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M, Mohsin SK, Hilsenbeck S, Schiff R. " Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. " Cancer Res.. 2006 Aug 15; 66 (16) : 8266-73.
Pubmed PMID: 16912207.
Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Dowsett M. " Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. " J. Clin. Oncol.. 2005 Apr 10; 23 (11) : 2469-76.
Pubmed PMID: 15753463.
Mohsin SK, Allred DC, Osborne CK, Cruz A, Otto P, Chew H, Clark GM, Elledge RM. " Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancer. " Breast Cancer Res. Treat.. 2005 Dec ; 94 (3) : 205-11.
Pubmed PMID: 16267611.
Rimawi MF, Mayer IA, Forero A, Nanda R, Goetz MP, Rodriguez AA, Pavlick AC, Wang T, Hilsenbeck SG, Gutierrez C, Schiff R, Osborne CK, Chang JC. " Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer: TBCRC 006. " J. Clin. Oncol.. 2013 Apr 8;
Pubmed PMID: 23569315.
Esteva FJ, Glaspy J, Baidas S, Laufman L, Hutchins L, Dickler M, Tripathy D, Cohen R, DeMichele A, Yocum RC, Osborne CK, Hayes DF, Hortobagyi GN, Winer E, Demetri GD. " Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. " J. Clin. Oncol.. 2003 Mar 15; 21 (6) : 999-1006.
Pubmed PMID: 12637463.
Ambrosone CB, Barlow WE, Reynolds W, Livingston RB, Yeh IT, Choi JY, Davis W, Rae JM, Tang L, Hutchins LR, Ravdin PM, Martino S, Osborne CK, Lyss AP, Hayes DF, Albain KS. " Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897. " J. Clin. Oncol.. 2009 Oct 20; 27 (30) : 4973-9.
Pubmed PMID: 19752340.
Mohsin SK, Weiss HL, Gutierrez MC, Chamness GC, Schiff R, Digiovanna MP, Wang CX, Hilsenbeck SG, Osborne CK, Allred DC, Elledge R, Chang JC. " Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. " J. Clin. Oncol.. 2005 Apr 10; 23 (11) : 2460-8.
Pubmed PMID: 15710948.
Choi JY, Barlow WE, Albain KS, Hong CC, Blanco JG, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff MD, Hayes DF, Ambrosone CB. " Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial. " Clin. Cancer Res.. 2009 Aug 15; 15 (16) : 5258-66.
Pubmed PMID: 19671875.
Migliaccio I, Wu MF, Gutierrez C, Malorni L, Mohsin SK, Allred DC, Hilsenbeck SG, Osborne CK, Weiss H, Lee AV. " Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer. " Breast Cancer Res. Treat.. 2010 Oct ; 123 (3) : 651-60.
Pubmed PMID: 19924529.
Glück S, Arteaga CL, Osborne CK. " Optimizing Chemotherapy-Free Survival for the ER/HER2-Positive Metastatic Breast Cancer Patient. " Clin. Cancer Res.. 2011 Sep 1; 17 (17) : 5559-61.
Pubmed PMID: 21764887.
Schiff R, Reddy P, Ahotupa M, Coronado-Heinsohn E, Grim M, Hilsenbeck SG, Lawrence R, Deneke S, Herrera R, Chamness GC, Fuqua SA, Brown PH, Osborne CK. " Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. " J. Natl. Cancer Inst.. 2000 Dec 6; 92 (23) : 1926-34.
Pubmed PMID: 11106684.
Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Tham YL, Kalidas M, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, Lewis MT, Wong H, O'Connell P. " Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. " J. Clin. Oncol.. 2005 Feb 20; 23 (6) : 1169-77.
Pubmed PMID: 15718313.
Come SE, Buzdar AU, Ingle JN, Arteaga CL, Brodie AM, Colditz GA, Johnston SR, Kristensen VN, Lønning PE, McDonnell DP, Osborne CK, Russo J, Santen RJ, Yee D, Hart CS. " Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement. " Clin. Cancer Res.. 2005 Jan 15; 11 (2) : 861s-4s.
Pubmed PMID: 15701878.
Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. " Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. " J. Clin. Oncol.. 2003 May 15; 21 (10) : 1973-9.
Pubmed PMID: 12743151.
Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF. " Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. " Lancet Oncol.. 2010 Jan ; 11 (1) : 55-65.
Pubmed PMID: 20005174.
Creighton CJ, Fu X, Hennessy BT, Casa AJ, Zhang Y, Gonzalez-Angulo AM, Lluch A, Gray JW, Brown PH, Hilsenbeck SG, Osborne CK, Mills GB, Lee AV, Schiff R. " Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. " Breast Cancer Res.. 2010 ; 12 (3) : R40.
Pubmed PMID: 20569503.
Hutchins LF, Green SJ, Ravdin PM, Lew D, Martino S, Abeloff M, Lyss AP, Allred C, Rivkin SE, Osborne CK. " Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-010 " J. Clin. Oncol.. 2005 Nov 20; 23 (33) : 8313-21.
Pubmed PMID: 16293862.
Oesterreich S, Zhang P, Guler RL, Sun X, Curran EM, Welshons WV, Osborne CK, Lee AV. " Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth. " Cancer Res.. 2001 Aug 1; 61 (15) : 5771-7.
Pubmed PMID: 11479214.
Osborne CK, Arteaga CL. " Role of molecular and genetic markers in breast cancer treatment decisions. " J. Clin. Oncol.. 2003 Dec 1; 21 (23) : 285s-287s.
Pubmed PMID: 14645413.
Rimawi MF, Wiechmann LS, Wang YC, Huang C, Migliaccio I, Wu MF, Gutierrez C, Hilsenbeck SG, Arpino G, Massarweh S, Ward R, Soliz R, Osborne CK, Schiff R. " Reduced Dose and Intermittent Treatment with Lapatinib and Trastuzumab for Potent Blockade of the HER Pathway in HER2/neu-Overexpressing Breast Tumor Xenografts. " Clin. Cancer Res.. 2011 Mar 15; 17 (6) : 1351-61.
Pubmed PMID: 21138857.
Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R. " Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. " J. Natl. Cancer Inst.. 2003 Mar 5; 95 (5) : 353-61.
Pubmed PMID: 12618500.
Jiang S, Meyer R, Kang K, Osborne CK, Wong J, Oesterreich S. " Scaffold attachment factor SAFB1 suppresses estrogen receptor alpha-mediated transcription in part via interaction with nuclear receptor corepressor. " Mol. Endocrinol.. 2006 Feb ; 20 (2) : 311-20.
Pubmed PMID: 16195251.
Come SE, Buzdar AU, Arteaga CL, Brodie AM, Davidson NE, Dowsett M, Ingle JN, Johnston SR, Lee AV, Osborne CK, Pritchard KI, Vogel VG, Winer EP, Hart CS. " Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement. " Clin. Cancer Res.. 2003 Jan ; 9 (1) : 443S-6S.
Pubmed PMID: 12538498.
Osborne CK, Evens A. " Select interviews from the 2011 San Antonio Breast Cancer Symposium (SABCS) and American Society of Hematology (ASH) Annual Meeting. " Oncology (Williston Park, N.Y.). 2011 Dec ; 25 (14) : 1422-4, 1426.
Pubmed PMID: 22329194.
Osborne CK, Zhao H, Fuqua SA. " Selective estrogen receptor modulators: structure, function, and clinical use. " J. Clin. Oncol.. 2000 Sep ; 18 (17) : 3172-86.
Pubmed PMID: 10963646.
Linden HM, Haskell CM, Green SJ, Osborne CK, Sledge GW, Shapiro CL, Ingle JN, Lew D, Hutchins LF, Livingston RB, Martino S. " Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313). " J. Clin. Oncol.. 2007 Feb 20; 25 (6) : 656-61.
Pubmed PMID: 17308269.
Pierce LJ, Hutchins LF, Green SR, Lew DL, Gralow JR, Livingston RB, Osborne CK, Albain KS. " Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. " J. Clin. Oncol.. 2005 Jan 1; 23 (1) : 24-9.
Pubmed PMID: 15545669.
Howell A, Osborne CK, Mauriac L. " Spreading the word, but not too thinly. " Lancet. 2004 Jan 10; 363 (9403) : 165-6.
Pubmed PMID: 14726176.
Huang C, Park CC, Hilsenbeck SG, Ward R, Rimawi MF, Wang YC, Shou J, Bissell MJ, Osborne CK, Schiff R. " ß1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. " Breast Cancer Res.. 2011 ; 13 (4) : R84.
Pubmed PMID: 21884573.
Healy NA, Heneghan HM, Miller N, Osborne CK, Schiff R, Kerin MJ. " Systemic mirnas as potential biomarkers for malignancy. " Int. J. Cancer. 2012 Nov 15; 131 (10) : 2215-22.
Pubmed PMID: 22618667.
Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, Schiff R. " Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. " Cancer Res.. 2008 Feb 1; 68 (3) : 826-33.
Pubmed PMID: 18245484.
Oesterreich S, Zhang Q, Hopp T, Fuqua SA, Michaelis M, Zhao HH, Davie JR, Osborne CK, Lee AV. " Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation. " Mol. Endocrinol.. 2000 Mar ; 14 (3) : 369-81.
Pubmed PMID: 10707955.
Divisova J, Kuiatse I, Lazard Z, Weiss H, Vreeland F, Hadsell DL, Schiff R, Osborne CK, Lee AV. " The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. " Breast Cancer Res. Treat.. 2006 Aug ; 98 (3) : 315-27.
Pubmed PMID: 16541323.
Ma XJ, Hilsenbeck SG, Wang W, Ding L, Sgroi DC, Bender RA, Osborne CK, Allred DC, Erlander MG. " The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. " J. Clin. Oncol.. 2006 Oct 1; 24 (28) : 4611-9.
Pubmed PMID: 17008703.
Stein D, Wu J, Fuqua SA, Roonprapunt C, Yajnik V, D'Eustachio P, Moskow JJ, Buchberg AM, Osborne CK, Margolis B. " The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer. " EMBO J.. 1994 Mar 15; 13 (6) : 1331-40.
Pubmed PMID: 7907978.
Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. " Treatment of HER2-positive breast cancer: current status and future perspectives. " Nat Rev Clin Oncol. 2011 ; 9 (1) : 16-32.
Pubmed PMID: 22124364.
Arpino G, Gutierrez C, Weiss H, Rimawi M, Massarweh S, Bharwani L, De Placido S, Osborne CK, Schiff R. " Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. " J. Natl. Cancer Inst.. 2007 May 2; 99 (9) : 694-705.
Pubmed PMID: 17470737.
Hershman DL, Unger JM, Barlow WE, Hutchins LF, Martino S, Osborne CK, Livingston RB, Albain KS. " Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897. " J. Clin. Oncol.. 2009 May 1; 27 (13) : 2157-62.
Pubmed PMID: 19307504.
Chen AC, Migliaccio I, Rimawi M, Lopez-Tarruella S, Creighton CJ, Massarweh S, Huang C, Wang YC, Batra SK, Gutierrez MC, Osborne CK, Schiff R. " Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies. " Breast Cancer Res. Treat.. 2012 Jul ; 134 (2) : 583-93.
Pubmed PMID: 22644656.

Funding

Cancer Center Support Grant #P30 CA125123-06: $1,875,245.00 (07/01/2007 - 06/30/2015); Grant funding from NIH; The mission of the DLDCC is to further reduce suffering and mortality from cancer through its research, education, patient care, and outreach activities. Our Center is a matrix cancer center with research members from nearly all College departments and academic units who have a commitment to cancer research and/or patient care. The DLDCC exists to facilitate the research of its members, to bring together researchers from different departments and centers for collaborative, multidisciplinary approaches to cancer, and to provide infrastructure support for the conduct of cancer research.

SPORE - Translational Research in Breast Cancer: $1,596,423.00 (07/01/2014 - 06/30/2019); Grant funding from NIH/NCI; The major goal of this large Specialized Program of Resource Excellence is to expedite the translation of basic research into applied clinical applications in breast cancer detection, treatment, and prevention. There are 4 Projects and 4 Cores Resources including a Pathology Resource and Tissue Resource.